Inflammatory Conditions - Tocilizumab Intravenous Products Utilization Management Medical Policy
Customize your policy alerts
Sign up for UCare POLICY: Inflammatory Conditions - Tocilizumab Intravenous Products Utilization Management Medical Policy alerts
Get alerted when POLICY: Inflammatory Conditions - Tocilizumab Intravenous Products Utilization Management Medical Policy changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and coverage criteria for intravenous tocilizumab products (Actemra, Avtozma, Tofidence) for UCare Medical Assistance and Exchange Plans. It outlines indications, dosing, step therapy (preferred product Tyenne), and authorization durations for approved indications.
Cytokine Release Syndrome Associated with Bispecific Antibodies was added as a condition of approval.
Graft‑Versus‑Host Disease was added as a condition of approval.
Immunotherapy‑Related Toxicities indication expanded from inflammatory arthritis to broader immunotherapy‑related toxicities associated with checkpoint inhibitors.
Giant Cell Arteritis steroid requirement changed to require the patient has tried or is currently taking a systemic corticosteroid unless contraindicated.
UCare added a preferred biosimilar step (Tyenne preferred) for patients new to therapy effective 1/1/2025.
Step therapy criteria were updated to require documentation of clinical need for a non-preferred product over preferred products, including chart note documentation to support that need.
Requirement changed to specify the patient has tried or is currently taking a systemic corticosteroid, unless contraindicated.
Cytokine release syndrome associated with bispecific antibodies and graft-versus-host disease were added as conditions of approval.
Indications and Medical Necessity Criteria
Cytokine Release Syndrome (CRS) associated with CAR T-cell therapy
Covered when BOTH dosing rules are met
Examples of CAR T-cell therapies are listed in policy
Giant Cell Arteritis (GCA)
Approve when ONE of the following is met
Objective measures examples provided (CRP, ESR, fever resolution, steroid dose reduction).
Polyarticular Juvenile Idiopathic Arthritis (polyarticular JIA)
Approve when ONE of the following is met
Rheumatoid Arthritis (RA)
Approve when ONE of the following is met
Systemic Juvenile Idiopathic Arthritis (sJIA) / Still's disease
Approve when ONE of the following is met
Castleman Disease (other use with supportive evidence)
Approve when ONE of the following is met
FDA-Approved Dosing
FDA‑Approved Indications — Approve dosing that meets BOTH of the following (A and B):
Castleman Disease (supportive evidence)
Castleman Disease — Approve for the duration noted if the patient meets ONE of the following (A or B):
Cytokine Release Syndrome (bispecific antibodies)
Cytokine Release Syndrome Associated with Bispecific Antibodies — Approve for 1 week if prescribed for a patient who has been or will be treated with a bispecific antibody.
Graft‑Versus‑Host Disease
Graft‑Versus‑Host Disease — Approve for the duration noted if the patient meets ONE of the following (A or B):
Immunotherapy‑Related Toxicities (checkpoint inhibitors)
Immunotherapy‑Related Toxicities Associated with Checkpoint Inhibitor Therapy — Approve for the duration noted if the patient meets ONE of the following (A or B):
Polymyalgia Rheumatica
Polymyalgia Rheumatica — Approve for the duration noted if the patient meets ONE of the following (A or B):
Still's Disease (AOSD)
Still's Disease, Adult Onset — Approve for the duration noted if the patient meets ONE of the following (A or B):
VEXAS Syndrome
VEXAS Syndrome — Approve for the duration noted if the patient meets ONE of the following (A or B):
Initial and indication-specific coverage criteria
Covered when ALL of the following are met
Step therapy updated to require this documentation
Replaces prior requirement of only a prior trial
Specialist list expanded
New conditions of approval added
The acute treatment of COVID-19 in hospitalized patients is not addressed by this policy. Although intravenous tocilizumab has an FDA‑recognized indication for certain hospitalized patients with COVID‑19, this specific policy does not target that indication and focuses on the other listed inflammatory and immune‑mediated conditions.
Coverage is not recommended for tocilizumab intravenous products for COVID‑19 outside the narrow hospitalized adult indication described in the product labeling. The policy also specifies that coverage is not recommended for Crohn’s disease based on available trial data, and for any circumstances not listed in the Recommended Authorization Criteria. Requests falling outside those listed indications are unlikely to be approved.
For Castleman disease initial therapy, the policy’s requirements related to HIV and HHV‑8 negativity and relapsed/refractory status were clarified to apply to unicentric disease (and not to multicentric disease) in recent revisions. This change modifies the prior initial‑therapy constraints so that viral status and relapsed/refractory requirements are only required for unicentric Castleman presentations.
Treatment of COVID‑19 in non‑hospitalized patients and any uses not listed in the policy’s Recommended Authorization Criteria are considered not recommended for approval (not medically necessary) under this policy. Requests for indications outside the listed criteria should be expected to be denied.
Requests for a non‑preferred tocilizumab product (non‑Tyenne) that do not include the required chart‑note documentation demonstrating clinical need may be considered not medically necessary. For patients new to therapy, the policy requires documentation supporting why the preferred biosimilar step cannot be used.
Dosing, Codes, and Administration Rules
| No codes listed |
| 8 mg/kg (max 800 mg) | Common maximum dosing per specified indications |
| 12 mg/kg | Dose allowed for patients < 30 kg in certain indications |
| 6 mg/kg (max 600 mg) | Dose specified for polymyalgia rheumatica |
Prior Authorization, Step Therapy, and Documentation Requirements
Prior Authorization Required and Step Therapy Risk
Prior authorization is required for tocilizumab intravenous products. Requests for non-preferred tocilizumab products (Actemra, Avtozma, Tofidence) may be denied unless step therapy requirements are met. When requesting a non-preferred product for patients new to therapy, chart notes documenting clinical need and the specific issue with all preferred product(s) (Tyenne) must be provided at time of request to justify override.
- Prior authorization required for tocilizumab IV products
- Tyenne is the preferred biosimilar; Actemra, Avtozma, and Tofidence are non-preferred
- Requests for non-preferred products may be denied if step therapy not met
Non-Preferred Product Documentation Required
If a non-preferred tocilizumab product is requested, the prescriber must supply chart notes demonstrating clinical need for the non-preferred product. Acceptable supporting documentation includes objective clinical data, prior treatment history, and documentation of allergy, intolerance, or therapeutic failure to all preferred product(s).
- Chart notes documenting the issue with all preferred product(s) must be provided at time of request
- Documentation may include objective measures, lab results, adverse reaction details, or prior treatment outcomes
- Patient or prescriber preference or facility stocking issues are not sufficient reasons for override
Specialist Requirement and Required Supporting Documentation
Prescriber documentation should include the prescriber specialty or documentation of consultation with an appropriate specialist. The specialist requirement has been expanded to include gastroenterologist, hepatologist, and pulmonologist in addition to previously accepted specialists (e.g., rheumatologist, oncologist, hematologist).
- Acceptable prescribers or consultants include rheumatologist, oncologist, hematologist, gastroenterologist, hepatologist, pulmonologist, and other condition-specific specialists
- For conditions such as Castleman disease, oncologist or hematologist consultation is expected
- For inflammatory or organ-specific conditions, include specialty consultation notes as applicable
Step Therapy Documentation and Criteria for Non-Preferred Product Approval
When requesting a non-preferred product for patients new to therapy, step therapy documentation must justify clinical need over the preferred biosimilar. Approval for a non-preferred biologic or biosimilar will be granted only if one of the enumerated issues (allergy to inactive ingredient, adverse reaction, therapeutic success with non-preferred and failure with all preferred products, or FDA indication mismatch) is documented with chart notes.
- One of A–D must be met and documented: A) allergic reaction to inactive ingredient in all preferred products; B) adverse reaction to inactive ingredient in all preferred products; C) therapeutic success on non-preferred and failure on all preferred products with chart documentation of adequate trials; D) diagnosis included in non-preferred FDA indications but not in preferred products' indications
- An adequate trial is generally considered ≥ 3 months unless otherwise specified
- Continuation-of-therapy overrides are not available to bypass required trial(s) of preferred products
Required Supporting Documentation — What to Submit
Required supporting documentation must accompany authorization requests and should include specialty prescriber or consultation notes, objective clinical measures when applicable, prior medication history, and specific chart notes explaining why preferred products are unsuitable.
- Include specialty consultation or clear documentation of prescriber specialty for the treated condition
- Provide objective measures (e.g., CRP, ESR, liver function tests, disease activity scores) where relevant
- Include prior treatment history, dates, responses, and reasons for discontinuation (e.g., allergy, intolerance, lack of efficacy)
- Chart note documentation is required at time of request to justify use of a non-preferred product
Drug and Clinical Background
Tocilizumab is an interleukin‑6 (IL‑6) receptor inhibitor indicated for multiple inflammatory and immune‑mediated conditions, including cytokine release syndrome (CRS) associated with CAR T‑cell therapy, giant cell arteritis, several juvenile idiopathic arthritis subtypes (including systemic JIA), rheumatoid arthritis, and Castleman disease. Dose modifications and monitoring are important due to risks such as elevated liver enzymes, neutropenia, and thrombocytopenia; dose interruption or modification recommendations generally follow guidance used in rheumatoid arthritis and are determined by the prescriber.
Key Terms and Dose Modification Guidance
Policy Updates and Review Dates
Updated step therapy criteria to require clinical need for non-preferred product over preferred products, including chart note documentation to support the need for a non-preferred product.
Added Cytokine Release Syndrome associated with bispecific antibodies and Graft‑Versus‑Host Disease as conditions of approval; expanded Immunotherapy‑Related Toxicities from inflammatory arthritis to checkpoint inhibitor–related toxicities and added prescriber attestation requirements.
Added gastroenterologist, hepatologist, and pulmonologist to the list of accepted specialists; removed prior use of subcutaneous product requirement for patients currently receiving tocilizumab and clarified examples of objective measures to include organ involvement and laboratory parameters.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.